Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 891065 +/- Ezabenlimab in Asian Advanced Solid Tumors
NCT04138823Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2019
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 891065 in solid tumor (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of Patients With Dose Limiting Toxicities (DLTs) in the MTD Evaluation Period at 21 days, Maximum Tolerated Dose (MTD) of BI 891065 at 21 days and 1 more. Started Nov 2019; status: completed.
02
Drugs
BI 891065
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04138823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04138823.